Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
LISINOPRIL DIHYDRATE HYDROCHLOROTHIAZIDE
Bristol-Myers Squibb Pharmaceuticals Ltd
20/12.5 Milligram
Tablets
2000-01-03
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Carace 20 Plus Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg lisinopril as dihydrate and 12.5 mg hydrochlorothiazide. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Tablets. Yellow, hexagonal, scored tablet with the product code ‘MSD 140’ on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Management of hypertension where a further reduction in blood pressure is required following the use of 20 mg lisinopril. Management of hypertension in patients who have been stabilised on the individual components. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS _Essential hypertension_ The usual dosage is one tablet, taken once daily. If necessary, the dosage may be increased by a small increment of either constituent. _Dosage renal insufficiency_ Thiazides may not be appropriate diuretics for use in patients with renal impairment and are ineffective at creatinine clearance values of 30ml/min or below (i.e. moderate or severe renal insufficiency). Carace 20 Plus is not to be used as initial therapy in any patient with renal insufficiency. In patients for whom therapy with Carace 20 Plus is intended, the state of renal function will have been established before introduction of lisinopril. Should there be pre-existing renal dysfunction, patients should be kept under regular surveillance for effects on blood urea and serum creatinine. In patients with creatinine clearance of >30 and < 80 ml/min, Carace 20 Plus may be used, but only after titration of the individual components. _Prior Diuretic Therapy_ Symptomatic hypotension may occur following the initial dose of Carace 20 Plus: this is more likely in patients who are volume and/or salt depleted as a result of prio Read the complete document